肝移植后注射疫苗无助于防治乙肝复发(2005.3.28)

zasxz

HBV Vaccination of Liver Transplant Recipients Is Not Effective for Prevention of HBV Recurrence

There are three primary options for the prevention of hepatitis B recurrence following liver transplantation: Hepatitis B immunoglobulin (HBIG) or lamivudine (Epivir-HBV) therapy or the combination of both. There have been anecdotal reports that HBV vaccination is a less costly option for prophylaxis that allows discontinuation of HBIG.

To?evaluate the effectiveness of HBV vaccination among patients receiving transplant for cirrhosis, researchers tested a double course of double dose recombinant HBV vaccine (Genhavac B).

Vaccination started 0ne month post HBIG discontinuation. Concomitant lamivudine was given throughout the study.

Fourteen patients enrolled in the study. The first vaccination cycle consisted of 0, 1-month and 6-month schedule. Nonresponders received a second cycle of 0, 1-month, 2-month cycle.

Results

One paient seroconverted after the first vaccination cycle. No pstients responded to the second vaccination clcle.

The authors conclude, ?/span>HBV vaccination in the post-transplantation setting does not seems like an effective strategy in the prophylaxis of HBV recurrence.?/span>

03/28/05

Reference Z Karasu and others. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. Journal of Viral Hepatitis 12(2): 212-215. March 2005.